Aarti Drugs Limited — PPTs, 06-05-2025: Investor Presentation

1. Financial Highlights:

Aarti Drugs posted Q4 revenue of Rs. 677 Cr, up 9% YoY, with EBITDA at Rs. 95 Cr (+10%) and margin steady at 14%. PAT rose 33% to Rs. 63 Cr, margin improving to 9.2% from 7.6%. For FY25, revenue declined 5% to Rs. 2,403 Cr due to volume softness; EBITDA dropped 5% to Rs. 303 Cr with margins at 12.6%. PAT stood at Rs. 168 Cr, maintaining a 7% margin. Gross margin improved by 200 bps YoY to 35.8%. Net debt was Rs. 615 Cr, with a net debt/equity ratio of 0.45 and strong operating cash flow of Rs. 224 Cr. Investments reflect in expanded gross block and capital work-in-progress.

2. Strategic Initiatives & Growth Drivers:

The company is focusing on brownfield capacity expansions in key APIs like Anti-Diabetic (Metformin), Anti-Protozoal, and Anti-Inflammatory segments. A Rs. 600 Cr capex over 4–5 years, funded mainly through internal accruals, aims to lift revenue to Rs. 4,200-4,500 Cr and improve margins. Backward integration efforts target cost efficiencies across API and formulations. R&D spend of about Rs. 46 Cr supports complex API and formulation development in niche areas such as Gliptins and skincare, focused on regulated markets including the US, Europe, and Latin America.

3. Business Developments:

Formulation exports are growing via subsidiary Pinnacle Life Science, with emphasis on Latin America and selected African markets. The company is registering new products and pursuing government tenders. Specialty chemicals capacity is being enhanced through multipurpose chloro-sulphonation lines. A strong pipeline spans anti-fungal, anti-diabetic, anti-inflammatory, and specialty chemical products.

4. Market Position & Competitive Advantage:

Aarti Drugs leads in specialty APIs with 50+ molecules and holds top global producer status for drugs like Nimesulide, Ketoconazole, and Metronidazole Benzoate. Its 13 manufacturing facilities boast WHO-GMP and USFDA approvals, supporting distribution in over 100 countries. High entry barriers from regulatory demands, capex, and R&D reduce competitive pressures. Diversified clients and geographic reach, combined with scale and procurement strength, mitigate risks and reinforce its competitive moat.

5. Investor Implications:

Q4 revenue growth and margin improvements indicate positive momentum despite FY25’s dip. The focused capex on specialized APIs and backward integration sets up revenue and margin expansion. Healthy cash flows and moderate leverage back financial flexibility. Execution risks include expanding capacities and scaling exports amid regulatory changes. The diversified portfolio, global footprint, and strong R&D capabilities suggest attractive long-term growth potential.